226 related articles for article (PubMed ID: 38604809)
1. Respiratory complex I regulates dendritic cell maturation in explant model of human tumor immune microenvironment.
Turpin R; Liu R; Munne PM; Peura A; Rannikko JH; Philips G; Boeckx B; Salmelin N; Hurskainen E; Suleymanova I; Aung J; Vuorinen EM; Lehtinen L; Mutka M; Kovanen PE; Niinikoski L; Meretoja TJ; Mattson J; Mustjoki S; Saavalainen P; Goga A; Lambrechts D; Pouwels J; Hollmén M; Klefström J
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604809
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.
Haikala HM; Anttila JM; Marques E; Raatikainen T; Ilander M; Hakanen H; Ala-Hongisto H; Savelius M; Balboa D; Von Eyss B; Eskelinen V; Munne P; Nieminen AI; Otonkoski T; Schüler J; Laajala TD; Aittokallio T; Sihto H; Mattson J; Heikkilä P; Leidenius M; Joensuu H; Mustjoki S; Kovanen P; Eilers M; Leverson JD; Klefström J
Nat Commun; 2019 Feb; 10(1):620. PubMed ID: 30728358
[TBL] [Abstract][Full Text] [Related]
3. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
[TBL] [Abstract][Full Text] [Related]
4. The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation.
Liu P; Zhao L; Zitvogel L; Kepp O; Kroemer G
Cell Death Differ; 2023 Dec; 30(12):2447-2451. PubMed ID: 37845384
[TBL] [Abstract][Full Text] [Related]
5. Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects.
Veeramachaneni R; Yu W; Newton JM; Kemnade JO; Skinner HD; Sikora AG; Sandulache VC
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230113
[TBL] [Abstract][Full Text] [Related]
6. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
Bahrambeigi S; Shafiei-Irannejad V
Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
[TBL] [Abstract][Full Text] [Related]
7. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Boidol B; Kornauth C; van der Kouwe E; Prutsch N; Kazianka L; Gültekin S; Hoermann G; Mayerhoefer ME; Hopfinger G; Hauswirth A; Panny M; Aretin MB; Hilgarth B; Sperr WR; Valent P; Simonitsch-Klupp I; Moriggl R; Merkel O; Kenner L; Jäger U; Kubicek S; Staber PB
Blood; 2017 Dec; 130(23):2499-2503. PubMed ID: 28972014
[TBL] [Abstract][Full Text] [Related]
8. PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax.
Serrat N; Guerrero-Hernández M; Matas-Céspedes A; Yahiaoui A; Valero JG; Nadeu F; Clot G; Di Re M; Corbera-Bellalta M; Magnano L; Rivas-Delgado A; Enjuanes A; Beà S; Cid MC; Campo E; Montero J; Hodson DJ; López-Guillermo A; Colomer D; Tannheimer S; Pérez-Galán P
Blood Adv; 2020 Sep; 4(17):4217-4231. PubMed ID: 32898249
[TBL] [Abstract][Full Text] [Related]
9. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
[TBL] [Abstract][Full Text] [Related]
10. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.
Talarico G; Orecchioni S; Dallaglio K; Reggiani F; Mancuso P; Calleri A; Gregato G; Labanca V; Rossi T; Noonan DM; Albini A; Bertolini F
Sci Rep; 2016 Jan; 6():18673. PubMed ID: 26728433
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth.
Madhavan K; Balakrishnan I; Lakshmanachetty S; Pierce A; Sanford B; Fosmire S; Elajaili HB; Walker F; Wang D; Nozik ES; Mitra SS; Dahl NA; Vibhakar R; Venkataraman S
Clin Cancer Res; 2022 Jun; 28(11):2409-2424. PubMed ID: 35344040
[TBL] [Abstract][Full Text] [Related]
12. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
[TBL] [Abstract][Full Text] [Related]
13. PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer.
Muttiah C; Whittle JR; Oakman C; Lindeman GJ
Future Oncol; 2022 May; 18(15):1805-1816. PubMed ID: 35187951
[TBL] [Abstract][Full Text] [Related]
14. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
Karjalainen R; Pemovska T; Popa M; Liu M; Javarappa KK; Majumder MM; Yadav B; Tamborero D; Tang J; Bychkov D; Kontro M; Parsons A; Suvela M; Mayoral Safont M; Porkka K; Aittokallio T; Kallioniemi O; McCormack E; Gjertsen BT; Wennerberg K; Knowles J; Heckman CA
Blood; 2017 Aug; 130(6):789-802. PubMed ID: 28619982
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade.
Kohlhapp FJ; Haribhai D; Mathew R; Duggan R; Ellis PA; Wang R; Lasater EA; Shi Y; Dave N; Riehm JJ; Robinson VA; Do AD; Li Y; Orr CJ; Sampath D; Raval A; Merchant M; Bhathena A; Salem AH; Hamel KM; Leverson JD; Donawho C; Pappano WN; Uziel T
Cancer Discov; 2021 Jan; 11(1):68-79. PubMed ID: 32887697
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.
Lee JB; Khan DH; Hurren R; Xu M; Na Y; Kang H; Mirali S; Wang X; Gronda M; Jitkova Y; MacLean N; Arruda A; Alaniz Z; Konopleva MY; Andreeff M; Minden MD; Zhang L; Schimmer AD
Blood; 2021 Jul; 138(3):234-245. PubMed ID: 34292323
[TBL] [Abstract][Full Text] [Related]
17. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells.
Ludwig LM; Hawley KM; Banks DB; Thomas-Toth AT; Blazar BR; McNerney ME; Leverson JD; LaBelle JL
Cell Death Dis; 2021 Oct; 12(11):1005. PubMed ID: 34707089
[TBL] [Abstract][Full Text] [Related]
19. Tumor Microenvironment-Triggered Charge Reversal Polymetformin-Based Nanosystem Co-Delivered Doxorubicin and IL-12 Cytokine Gene for Chemo-Gene Combination Therapy on Metastatic Breast Cancer.
Sun Y; Liu L; Zhou L; Yu S; Lan Y; Liang Q; Liu J; Cao A; Liu Y
ACS Appl Mater Interfaces; 2020 Oct; 12(41):45873-45890. PubMed ID: 32924511
[TBL] [Abstract][Full Text] [Related]
20. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
